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M
uch scientific attention is currently
focused on the possible role of sele-
nium as an antineoplastic drug and
the hypothetical involvement of this trace ele-
ment in the etiology of human cancer. Great in-
terest has been shown for some of the effects
that pharmacological doses of selenium have on
cell proliferation and viability, suggesting the
possible use of selenium compounds as antine-
oplastic drugs.1,2 The serious toxicity of several
selenium compounds, which seems to be stric-
tly related to the carcinostatic and cytotoxic ac-
tivity of these compounds,3 however, hampers
their consideration in clinical practice. The epi-
demiologic evidence linking selenium exposure
to human cancer appears inconsistent, due to
the conflicting results of recent ecologic investi-
gations4-6 and case-control studies with both
cross-sectional and prospective design.7,8 In fact,
no association, an inverse one and a direct asso-
ciation between selenium exposure and cancer
have been observed in these investigations. A
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ABSTRACT
Background. Increased mortality from lymphoid malignancies following exposure to environmen-
tal selenium has recently been reported. Moreover, conflicting results have been found in investiga-
tions examining the relationship between serum concentrations of selenium and some clinical featu-
res of malignant lymphoproliferative diseases.
Methods. Serum concentrations of selenium were analyzed by atomic absorption spectrometry in
fifty-nine patients with newly diagnosed chronic lymphoid malignancies and in forty control subjects 
Results. Selenium concentrations were significantly lower in patients than in control subjects. Ho-
wever, when only patients with localized disease were compared to controls, no significant difference
in serum selenium concentrations was observed. Clinical stage was inversely associated with sele-
nium levels. High-grade non-Hodgkin’s lymphoma was characterized by lower selenium levels than
low-grade and intermediate-grade disease. Selenium levels were positively associated with albumin
and hemoglobin, and inversely correlated with serum concentrations of _-2-microglobulin and with
erythrocyte sedimentation rate.
Conclusions. The findings of this study do not suggest that a high selenium intake represents a risk
factor for malignant lymphoproliferative diseases, but limitations of the investigation hamper eva-
luation of the results. The possible utility of determining serum concentrations of selenium in the
clinical evaluation of patients with lymphoid malignancies merits examination in larger studies.
Key words: selenium, serum, lymphoproliferative disorders, Hodgkin’s disease; non-Hodgkin’s lymphoma, multiple
myeloma, chronic lymphocytic leukemia, neoplasms
tendency toward a positive association between
selenium intake and the subsequent incidence
of cancer has recently been reported in a large
cohort-nested case-control study.9
Neoplasms of the lymphoid system represent
one of the most frequently examined site-speci-
fic cancers in case-control studies with cross-
sectional design for analyzing the possible rela-
tionship between serum concentrations of sele-
nium and cancer,10-16 but the results of these
studies have been conflicting. In two investiga-
tions a tendency toward higher selenium levels
in patients with reticuloendothelial neoplasms10
and with Hodgkin’s disease11 was observed,
whereas significantly low serum concentrations
of selenium were reported in patients affected
by chronic lymphocytic leukemia12 and epider-
motropic cutaneous T-cell lymphoma.16 More-
over,  different results were obtained in these
studies regarding the association between sele-
nium status and the clinical stage of the neo-
plasms.
In a recent cohort study examining cancer
mortality following accidental exposure to he-
xavalent selenium through drinking water, a hi-
gher mortality from non-Hodgkin’s lymphoma
and lymphoid malignancies was seen in fema-
les.17 Moreover, in a cohort of Baltic Sea fisher-
men, a higher mortality from multiple myelo-
ma was observed in subjects whose diets pro-
vide a significant supplementation of selenium
as well as other nutrients and pollutants.18
These observations led us to examine the se-
rum levels of selenium in patients with newly
diagnosed lymphoid malignancies and the possi-
ble association between the levels of this trace
element and some clinical features of the disease.
Materials and Methods
A consecutive series of fifty-nine patients
with suspected or newly diagnosed chronic
lymphoid malignancies (Hodgkin’s disease,
non-Hodgkin’s lymphoma, multiple myeloma
and chronic lymphocytic leukemia) referred to
the Hematology Service of S. Maria Nuova Ho-
spital in Reggio Emilia, northern Italy, were en-
rolled in the study. None of the patients had be-
en previously treated. 
Venous blood drawn in the morning after
overnight fasting was immediately centrifuged
for 10 min, and two serum aliquots of 1.5 mL
from each patient were stored in plastic tubes at
–12°C until analysis. In four cases, diagnosis of
malignant lymphoproliferative disease was not
confirmed, and these subjects were removed
from the investigation. Eight of the patients in-
cluded in the study (4 males and 4 females) we-
re affected by Hodgkin’s disease, 39 (27 males
and 12 females) by non-Hodgkin’s lymphoma,
7 (5 males and 2 females) by multiple myeloma
and 5 (2 males and 3 females) by chronic lym-
phocytic leukemia. 
The following hematologic parameters were
also determined in several patients: erythrocyte
sedimentation rate, hemoglobin, serum levels
of albumin, b2-microglobulin, serum lactate
dehydrogenase and copper.
Four general practitioners from the Local He-
alth Unit in Reggio Emilia were asked to select a
sample of the individuals on their rolls. Forty
controls, 17 males and 23 females, agreed to
participate in the study following an invitation
from their family doctors and were referred to
the Hematology Service. Blood samples from
these individuals were obtained following the
same procedures used in the patients.
Serum selenium was determined at the Labo-
ratory of Industrial Toxicology of the Depar-
tment of Occupational Health of Scandiano,
Reggio Emilia, using atomic absorption spec-
trometry.19 A graphite furnace Perkin-Elmer
4100ZL atomic absorption spectrometer with
background Zeeman correction was used for
the analyses. Determinations were made in du-
plicate, and the analysts were blinded as to the
case status of the specimens.
Spearmans rank correlation analysis was used
to examine the relationship between serum se-
lenium levels and age in the study population,
and between selenium and the remaining he-
matologic variables in patients. Unpaired Stu-
dent’s t-test, analysis of variance and analysis of
covariance were used for comparisons between
means. A two-tailed p-value of less than 0.05
was considered significant in all procedures.
The statistical analyses were carried out using
the SPSS/PC+ software.
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Results
Selenium concentrations were 92.3±13.6
mg/L in control subjects (100.2±12 mg/L in ma-
les and 86.5±11.8 mg/L in females) and
82.6±15.5 mg/L (83.6±15.5 mg/L in males and
80.6±15.6 mg/L in females) in patients with
lymphoid malignancies (p<0.05 vs. controls -
Table 1). The difference in selenium concentra-
tions between males and females was statistical-
ly significant in control subjects (p=0.001) but
not in patients (p=0.479). In control subjects,
age was not significantly correlated with serum
selenium (p=0.759), whereas a significant in-
verse correlation was observed in patients
(p=0.002). Serum concentrations of selenium
in the different lymphoid malignancies are
shown in Table 1. In comparison with controls,
the serum levels of selenium were significantly
lower in patients with non-Hodgkin’s lympho-
ma (p<0.05) and multiple myeloma (p<0.001).
Further adjustment for gender in the statistical
analysis made the differences between controls
and patients with non-Hodgkin’s lymphoma si-
gnificant at a p-level<0.001.
Serum selenium concentrations according to
clinical stage in patients with non-Hodgkin’s
lymphoma are shown in Table 2. These concen-
trations were inversely associated with stage,
and statistically significant differences were ob-
served between patients with stage IV and stage
I lymphoma. Results did not change significan-
tly after adjustment for gender. Levels of sele-
nium in stage I-II lymphomas were not signifi-
cantly different from the values observed in
control subjects, whereas selenium concentra-
tions in stage IV disease were significantly lower
than in with controls (p<0.001). A tendency
toward lower levels of selenium in patients with
more advanced disease was also observed in
Hodgkins disease, multiple myeloma and chro-
nic lymphocytic leukemia. In subjects with
Hodgkins disease, selenium concentrations we-
re 96.8±6, 90.3±4.7 and 75.7 mg/L, respectively,
in patients with stage I (n=3), stage II (n=4)
and stage III (n=1) disease.
In patients with non-Hodgkin’s lymphoma,
serum selenium was higher in intermediate-
grade and lower in high-grade disease in com-
parison with low-grade disease (Table 3). Diffe-
rences among the three groups were not stati-
stically significant, but when clinical stage was
included in the analysis as a confounder, a p-
value of 0.003 was obtained. After adjustment
for stage, selenium in patients with high-grade
lymphoma was not significantly lower than in
patients with low-grade disease (p=0.054),
whereas the difference between high-grade and
intermediate-grade disease was statistically si-
gnificant (p<0.001). The difference in serum
selenium concentrations between subjects with
low-grade lymphoma and intermediate-grade
disease was not statistically significant
(p=0.119). The presence of systemic symptoms
in non-Hodgkin’s lymphoma and Hodgkin’s di-
sease was not associated with significant diffe-
rences in selenium concentrations with respect
to patients without these symptoms. The level
of selenium in the thirty-five patients with non-
Hodgkins lymphoma reporting the presence of
systemic symptoms was 83.7±15.2 mg/L, while
in the remaining four patients with lymphoma
not reporting systemic symptoms selenium
Table 1. Serum selenium levels (mean value1SD) in control subjects and in
patients with lymphoid malignancies.
n age (yr) selenium (µg/L) 
control subjects 40 50.0±14.5 92.3±13.6
lymphoid malignancies 59 58.4±15.7* 82.6±15.5* 
Hodgkin’s disease 8 35.9±8.9* 90.9±8.2
non-Hodgkin’s lymphoma 39 60.8±14.5* 83.2±14.9*
multiple myeloma 7 65.3±10.7* 69.1±18.8°
chronic lymphocytic leukemia 5 65.8±4.9* 83.2±15.8
*p<0.05 vs. control subjects; °p<0.001 vs. control subjects
Table 2. Serum selenium levels in patients with non-Hodgkin’s lymphoma
according to clinical stage of the disease. Results are expressed as mean
1SD (number of subjects).
selenium (µg/L)
non-Hodgkin’s lymphoma:
stage 1 95.8±15.4 (9)
stage 2 89.4±7.4 (6)
stage 4 76.9±12.7 (24)*°
*p<0.001 vs. control subjects; °p=0.001 vs. patients with stage 1 disease.
 
concentrations were 78.9±12.8 5 g/L (p=0.55).
In patients with lymphoid malignancies, sele-
nium levels correlated positively with albumin
and hemoglobin, whereas an inverse associa-
tion with erythrocyte sedimentation rate and
b2-microglobulin was observed. Serum levels
of copper and lactate dehydrogenase did not
correlate with selenium concentrations. When
analysis was restricted to patients with non-
Hodgkin’s lymphoma (Table 4), the results did
not change significantly.
Discussion
In the present study, patients with newly dia-
gnosed malignant lymphoproliferative diseases
were found to have lower serum selenium levels
than control subjects, but this difference was
entirely due to the low selenium concentrations
in patients with advanced disease. The findings
of the study are in accordance with observa-
tions made in chronic lymphocytic leukemia13
and in epidermotropic cutaneous T-cell lym-
phoma,16 which show a tendency for serum se-
lenium levels to decrease with progression of
the disease, and that selenium levels in patients
with early disease stages were not significantly
different from the values observed in controls.
In two other investigations which examined the
relationship between the stage of lymphoid ma-
lignancies and serum selenium concentra-
tions,11,12 no apparent association was observed,
and serum selenium levels in the whole patient
group were not significantly different from the
values observed in controls. Most of the patien-
ts examined in one of these investigations, ho-
wever, had already received treatment for the
disease.11 The influence of therapy on serum se-
lenium levels in lymphoid malignancies is con-
troversial since it has been associated with ei-
ther increased11 to normal12 serum selenium
concentrations. It has been suggested that che-
motherapy or radiotherapy might increase the
release of selenium into the blood from the ne-
oplastic tissue,10,11 which (as will be discussed la-
ter) has, at least in some types of tumors, a hi-
gher selenium content than the remaining tis-
sues.20-23
The inverse association between progression
of lymphoid malignancies and selenium status
observed in the present study is consistent with
previous observations in patients with cancer,24-27
although not all studies concur.28,29 The decrea-
sing concentrations of selenium with disease
progression might be due to disease-mediated
dietary changes, which are more pronounced in
patients with advanced disease. This hypothesis,
however, was not tested in the present study or
in previous investigations, to the best of our
knowledge. In the patients with Hodgkin’s dise-
ase and lymphoma examined in this study, ho-
wever, no association was observed between se-
lenium status and the presence of systemic sym-
ptoms, which might also have been linked to
changes in dietary habits. A second hypothesis
to explain the decreasing levels of selenium in
untreated cancer patients with very advanced
disease arises from the observation that sele-
nium compounds tend to concentrate in neo-
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Table 3. Serum selenium concentrations (µg/L) in patients with non-Hod-
gkin’s lymphoma according to grade of the disease. Results are expressed
as mean1SD (n)
low grade intermediate grade high grade p* p°
selenium levels 
80.7±11.7(17) 87.7±16.6(17) 76.3±17.1(5) 0.515 0.003
adjusted# selenium levels
84.8 90.8 69.1 
*p-value at analysis of variance among the diagnostic groups; °p-value at analysis
of variance among the diagnostic groups adjusting for clinical stage; #adjusted for
clinical stage.
Table 4. Correlation between serum selenium concentrations and hemato-
logic parameters in patients with non-Hodgkin's lymphoma.*
S° p-value
albumin 0.413 0.011
b2-microglobulin –0.471 0.018
lactate-dehydrogenase –0.270 0.123
copper –0.030 0.869
erythrocyte sedimentation rate –0.410 0.012
hemoglobin 0.376 0.018
*determinations were available in 37 patients for albumin, in 25 for b2-microglobu-
lin, in 34 for lactate dehydrogenase, in 32 for copper, in 37 for erythrocyte sedimenta-
tion rate and in 39 for hemoglobin; °Spearman’s rank correlation coefficient.
 
plastic tissues in a variety of human and animal
tumors.20-23,30-34 This phenomenon, which has be-
en specifically examined in patients with Hod-
gkin’s disease and non-Hodgkin’s lymphoma
and in animal models of lymphoma,30,32-34 repre-
sents the basis for the clinical use of labelled se-
lenium compounds in tumor scintigraphy. En-
hanced uptake of selenium by the neoplastic tis-
sue might be responsible for depleting the trace
element content of the blood and other tissues,
thereby lowering serum selenium concentra-
tions. It has also been noted in in vivo and in vi-
tro animal studies that preferential uptake of la-
belled selenium compounds decreases following
tumor irradiation,35 and this fact might explain
the lack of association between serum levels of
selenium and the stage of the lymphoid mali-
gnancy when treated patients were examined.11
The association observed in the present study
between the grade of non-Hodgkin’s lympho-
ma and selenium status suggests that high-gra-
de lymphomas are linked to the lowest serum
concentrations of the trace element. The num-
ber of patients with high-grade lymphoma, ho-
wever, was very low and therefore these results
must be evaluated with caution, especially since
serum levels of selenium were higher in patients
with intermediate-grade lymphoma than in
those with low-grade disease. A tendency
toward higher selenium concentrations in pa-
tients with well-differentiated lymphoid mali-
gnancies and non-Hodgkin’s lymphoma has
been reported.11,12 The absence in the present
study of a relationship between serum selenium
levels and the presence of systemic symptoms in
patients with Hodgkins disease and lymphoma
confirms previous reports.12
In agreement with observations in patients
with cancer and other diseases,13,36,37 but unlike
what was found in a group of patients with reti-
culoendothelial tumors,11 a significant correla-
tion between selenium levels and albumin was
detected in the overall patient group as well as
in the group with non-Hodgkin’s lymphoma. A
direct association between albumin and serum
selenium levels might be explained by nutritio-
nal factors or by the fact that albumin represen-
ts a selenium-containing protein.38 A variation
in albumin and selenium independently indu-
ced by the progression of the lymphoid neo-
plasm might also be hypothesized. The associa-
tion between hemoglobin and serum selenium
observed in the present study in patients with
non-Hodgkin’s lymphoma was not supported
in a previous investigation.11 No other study, to
our knowledge, has analyzed a possible associa-
tion between selenium levels and erythrocyte
sedimentation rate, serum levels of lactate de-
hydrogenase, copper and b2-microglobulin in
patients with non-Hodgkin’s lymphoma. The
inverse correlation of erythrocyte sedimenta-
tion rate and b2-microglobulin with selenium
found in this investigation deserves to be analy-
zed in larger studies.
Since in the present work a relationship was
observed between serum selenium levels and
hematologic parameters, stage and, in non-
Hodgkin’s lymphoma, grade, it seems appro-
priate to examine the possible utility of deter-
mining selenium status in the clinical evalua-
tion of patients with lymphoid malignancies.
Larger studies however are required to evaluate
this possibility. Moreover, selenium status mar-
kers at clinical onset of a lymphoproliferative
malignancy might represent a prognostic factor
of the disease, as recently suggested in epider-
motropic cutaneous T-cell lymphoma.16 Serum
levels of selenium should therefore be conside-
red for inclusion in future follow-up studies to-
gether with the prognostic factors identified so
far or suggested in Hodgkins disease39 and lym-
phoma.40 The patients with non-Hodgkins lym-
phoma examined in the present study have be-
en entered in a follow-up in order to analyze
the possible relationship between serum levels
of selenium at diagnosis of the disease and re-
sponse to chemiotherapy.
The findings of this study do not suggest that
overexposure to selenium represents a risk fac-
tor for lymphoid malignancies since the levels
of selenium in patients affected by stage I Hod-
gkin’s disease and non-Hodgkin’s lymphoma
were only slightly elevated with respect to con-
trols, whereas the number of patients affected
by early-stage multiple myeloma and chronic
lymphocytic leukemia was insufficient to yield
meaningful data. Due to the cross-sectional de-
sign of the study, the above mentioned hypo-
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thesis cannot be entirely ruled out however. In
fact even in patients with localized disease, a di-
sease-mediated decrease in serum selenium le-
vels, a sensitive short-term marker of selenium
intake and status,41,42 cannot be excluded, and
this interferes with our ability to establish posi-
tive association between selenium intake and
lymphoid malignancies. Moreover, the cancer-
enhancing properties of selenium observed in
some animal studies have been selectively asso-
ciated with specific chemical forms of the trace
element, such as hexavalent43 or tetravalent44
inorganic selenium, suggesting that analysis of
exposure rather than evaluation of selenium
status might be useful for detecting an associa-
tion between selenium and human cancer. Nor
do the results of the present study suggest that a
low selenium status represents a risk factor for
lymphoid malignancies, since the serum con-
centrations of selenium in patients with locali-
zed disease were no lower than those observed
in controls. The results of this investigation do
not however rule out a possible involvement of
selenium in the etiology of lymphoid malignan-
cies at intake levels considerably higher or lower
than those typical of the Italian population exa-
mined in the study.
In conclusion, the results of the present study
suggest that the serum concentration of sele-
nium in newly diagnosed lymphoid malignan-
cies is inversely associated with the clinical stage
of the disease, but this relationship needs to be
confirmed in larger studies. This investigation
does not support the hypothesis of an involve-
ment of high selenium intake in the etiology of
malignant lymphoproliferative diseases, but the
limitations of the study do not allow definitive
conclusions to be drawn on this topic.
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